Abivax SA (FR:ABVX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abivax SA shares uplifting interim study results showing that patients with moderate to severe ulcerative colitis (UC) maintained clinical remission over two years using a reduced 25 mg daily dose of obefazimod. This maintenance study, part of a longer-term assessment of up to six years, confirms the drug’s efficacy and tolerability. The findings suggest obefazimod could be a promising long-term oral treatment option for UC patients.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
